Baidu
map

AIDS:四氢大麻酚(THC),可能会减缓高达50%的HIV患者的精神衰退!

2017-12-13 白木清水 来宝网

一项研究表明,在大麻中发现的一种化学物质——四氢大麻酚(THC),可能会减缓高达50%的HIV患者的精神衰退。

一项研究表明,在大麻中发现的一种化学物质——四氢大麻酚(THC),可能会减缓高达50%的HIV患者的精神衰退

这项研究的主要作者诺伯特·卡明斯基(Norbert Kaminski)说:“人们相信,在许多艾滋病患者中,认知功能会减少,部分原因是大脑中出现了慢性炎症。”“这是因为免疫系统不断被刺激来对抗疾病。”

Kaminski和他的合着者Mike Rizzo是一名毒理学的研究生,他发现大麻中的化合物能够起到消炎药的作用,减少了被称为单核细胞的炎性白血球的数量,减少了它们在体内释放的蛋白质。

Rizzo说:“这种细胞的减少可能会减缓甚至停止发炎的过程,这可能会帮助病人延长他们的认知功能。”

这两名研究人员采集了40名HIV患者的血液样本,他们报告了他们是否吸食过大麻。然后,他们从每个捐赠者体内分离出白细胞,研究炎症细胞水平和大麻对细胞的影响。

卡明斯基说:“与使用大麻的患者相比,不吸大麻的病人有很高的炎症细胞。”“事实上,那些使用大麻的人与没有感染艾滋病毒的健康人相当接近。”

自1990年以来,MSU综合毒理学研究所所长Kaminski研究了大麻对免疫系统的影响。他的实验室是第一个发现可以在免疫细胞表面结合大麻化合物的蛋白质的实验室。直到那时,还不清楚这些化合物是如何影响免疫系统的,也被称为大麻素。

艾滋病毒是人类免疫缺陷病毒,它可以破坏或改变保护人体免疫细胞的功能。抗逆转录病毒疗法是一种标准的治疗方法,其中包括一种药物的混合物来抵御病毒——这些细胞有更好的机会保持原状。

然而,即使有了这种疗法,某些白血球仍然可以过度刺激,最终变得发炎。

Rizzo说:“我们将继续研究这些细胞,以及它们是如何相互作用和引起炎症的。”“我们从中学到的东西对其他与大脑有关的疾病,如阿尔茨海默氏症和帕金森氏病也有影响,因为发现了同样的炎症细胞。”

了解更多的这种互动最终可能会带来新的治疗药物,帮助HIV患者保持他们的精神功能。

原始出处

Rizzo Michael, Crawford Robert B, Henriquez Joseph E, et al. HIV-infected cannabis users have lower circulating CD16+ monocytes and IP-10 levels compared to non-using HIV patients.AIDS, Post Acceptance: November 30, 2017.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2003358, encodeId=24092003358c6, content=<a href='/topic/show?id=5012890397' target=_blank style='color:#2F92EE;'>#HIV患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8903, encryptionId=5012890397, topicName=HIV患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Thu May 17 08:42:00 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335876, encodeId=51803358e66b, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55a22015915, createdName=1e1ff052m13(暂无匿称), createdTime=Thu Aug 02 23:36:43 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033858, encodeId=3d6b20338581a, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Sun Feb 25 03:42:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272711, encodeId=d3f412e2711d4, content=<a href='/topic/show?id=d04f440581e' target=_blank style='color:#2F92EE;'>#大麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44058, encryptionId=d04f440581e, topicName=大麻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Thu Dec 14 23:42:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365637, encodeId=4981136563e7f, content=<a href='/topic/show?id=41fa21e036' target=_blank style='color:#2F92EE;'>#AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2170, encryptionId=41fa21e036, topicName=AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbcc223, createdName=cooco, createdTime=Thu Dec 14 23:42:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269161, encodeId=82b826916144, content=学习学习.了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Dec 13 17:06:05 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269075, encodeId=28ee2690e5a4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/DYAIOgq83er6Gnp47UKDBUh7BiadBKe2SjdBiaibNuYmwTGkrrE34N3iaoneZnFibSziaXicAMbqIkTod8ibbI9nTwOB7w/0, createdBy=9fa32173975, createdName=兰亭序123, createdTime=Wed Dec 13 09:12:40 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269074, encodeId=8fb32690e48d, content=学习一下知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Wed Dec 13 09:10:36 CST 2017, time=2017-12-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2003358, encodeId=24092003358c6, content=<a href='/topic/show?id=5012890397' target=_blank style='color:#2F92EE;'>#HIV患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8903, encryptionId=5012890397, topicName=HIV患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Thu May 17 08:42:00 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335876, encodeId=51803358e66b, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55a22015915, createdName=1e1ff052m13(暂无匿称), createdTime=Thu Aug 02 23:36:43 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033858, encodeId=3d6b20338581a, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Sun Feb 25 03:42:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272711, encodeId=d3f412e2711d4, content=<a href='/topic/show?id=d04f440581e' target=_blank style='color:#2F92EE;'>#大麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44058, encryptionId=d04f440581e, topicName=大麻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Thu Dec 14 23:42:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365637, encodeId=4981136563e7f, content=<a href='/topic/show?id=41fa21e036' target=_blank style='color:#2F92EE;'>#AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2170, encryptionId=41fa21e036, topicName=AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbcc223, createdName=cooco, createdTime=Thu Dec 14 23:42:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269161, encodeId=82b826916144, content=学习学习.了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Dec 13 17:06:05 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269075, encodeId=28ee2690e5a4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/DYAIOgq83er6Gnp47UKDBUh7BiadBKe2SjdBiaibNuYmwTGkrrE34N3iaoneZnFibSziaXicAMbqIkTod8ibbI9nTwOB7w/0, createdBy=9fa32173975, createdName=兰亭序123, createdTime=Wed Dec 13 09:12:40 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269074, encodeId=8fb32690e48d, content=学习一下知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Wed Dec 13 09:10:36 CST 2017, time=2017-12-13, status=1, ipAttribution=)]
    2018-08-02 1e1ff052m13(暂无匿称)

    学习了,学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2003358, encodeId=24092003358c6, content=<a href='/topic/show?id=5012890397' target=_blank style='color:#2F92EE;'>#HIV患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8903, encryptionId=5012890397, topicName=HIV患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Thu May 17 08:42:00 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335876, encodeId=51803358e66b, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55a22015915, createdName=1e1ff052m13(暂无匿称), createdTime=Thu Aug 02 23:36:43 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033858, encodeId=3d6b20338581a, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Sun Feb 25 03:42:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272711, encodeId=d3f412e2711d4, content=<a href='/topic/show?id=d04f440581e' target=_blank style='color:#2F92EE;'>#大麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44058, encryptionId=d04f440581e, topicName=大麻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Thu Dec 14 23:42:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365637, encodeId=4981136563e7f, content=<a href='/topic/show?id=41fa21e036' target=_blank style='color:#2F92EE;'>#AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2170, encryptionId=41fa21e036, topicName=AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbcc223, createdName=cooco, createdTime=Thu Dec 14 23:42:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269161, encodeId=82b826916144, content=学习学习.了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Dec 13 17:06:05 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269075, encodeId=28ee2690e5a4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/DYAIOgq83er6Gnp47UKDBUh7BiadBKe2SjdBiaibNuYmwTGkrrE34N3iaoneZnFibSziaXicAMbqIkTod8ibbI9nTwOB7w/0, createdBy=9fa32173975, createdName=兰亭序123, createdTime=Wed Dec 13 09:12:40 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269074, encodeId=8fb32690e48d, content=学习一下知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Wed Dec 13 09:10:36 CST 2017, time=2017-12-13, status=1, ipAttribution=)]
    2018-02-25 wjywjy
  4. [GetPortalCommentsPageByObjectIdResponse(id=2003358, encodeId=24092003358c6, content=<a href='/topic/show?id=5012890397' target=_blank style='color:#2F92EE;'>#HIV患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8903, encryptionId=5012890397, topicName=HIV患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Thu May 17 08:42:00 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335876, encodeId=51803358e66b, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55a22015915, createdName=1e1ff052m13(暂无匿称), createdTime=Thu Aug 02 23:36:43 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033858, encodeId=3d6b20338581a, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Sun Feb 25 03:42:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272711, encodeId=d3f412e2711d4, content=<a href='/topic/show?id=d04f440581e' target=_blank style='color:#2F92EE;'>#大麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44058, encryptionId=d04f440581e, topicName=大麻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Thu Dec 14 23:42:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365637, encodeId=4981136563e7f, content=<a href='/topic/show?id=41fa21e036' target=_blank style='color:#2F92EE;'>#AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2170, encryptionId=41fa21e036, topicName=AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbcc223, createdName=cooco, createdTime=Thu Dec 14 23:42:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269161, encodeId=82b826916144, content=学习学习.了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Dec 13 17:06:05 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269075, encodeId=28ee2690e5a4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/DYAIOgq83er6Gnp47UKDBUh7BiadBKe2SjdBiaibNuYmwTGkrrE34N3iaoneZnFibSziaXicAMbqIkTod8ibbI9nTwOB7w/0, createdBy=9fa32173975, createdName=兰亭序123, createdTime=Wed Dec 13 09:12:40 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269074, encodeId=8fb32690e48d, content=学习一下知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Wed Dec 13 09:10:36 CST 2017, time=2017-12-13, status=1, ipAttribution=)]
    2017-12-14 kcb069
  5. [GetPortalCommentsPageByObjectIdResponse(id=2003358, encodeId=24092003358c6, content=<a href='/topic/show?id=5012890397' target=_blank style='color:#2F92EE;'>#HIV患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8903, encryptionId=5012890397, topicName=HIV患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Thu May 17 08:42:00 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335876, encodeId=51803358e66b, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55a22015915, createdName=1e1ff052m13(暂无匿称), createdTime=Thu Aug 02 23:36:43 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033858, encodeId=3d6b20338581a, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Sun Feb 25 03:42:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272711, encodeId=d3f412e2711d4, content=<a href='/topic/show?id=d04f440581e' target=_blank style='color:#2F92EE;'>#大麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44058, encryptionId=d04f440581e, topicName=大麻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Thu Dec 14 23:42:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365637, encodeId=4981136563e7f, content=<a href='/topic/show?id=41fa21e036' target=_blank style='color:#2F92EE;'>#AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2170, encryptionId=41fa21e036, topicName=AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbcc223, createdName=cooco, createdTime=Thu Dec 14 23:42:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269161, encodeId=82b826916144, content=学习学习.了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Dec 13 17:06:05 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269075, encodeId=28ee2690e5a4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/DYAIOgq83er6Gnp47UKDBUh7BiadBKe2SjdBiaibNuYmwTGkrrE34N3iaoneZnFibSziaXicAMbqIkTod8ibbI9nTwOB7w/0, createdBy=9fa32173975, createdName=兰亭序123, createdTime=Wed Dec 13 09:12:40 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269074, encodeId=8fb32690e48d, content=学习一下知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Wed Dec 13 09:10:36 CST 2017, time=2017-12-13, status=1, ipAttribution=)]
    2017-12-14 cooco
  6. [GetPortalCommentsPageByObjectIdResponse(id=2003358, encodeId=24092003358c6, content=<a href='/topic/show?id=5012890397' target=_blank style='color:#2F92EE;'>#HIV患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8903, encryptionId=5012890397, topicName=HIV患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Thu May 17 08:42:00 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335876, encodeId=51803358e66b, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55a22015915, createdName=1e1ff052m13(暂无匿称), createdTime=Thu Aug 02 23:36:43 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033858, encodeId=3d6b20338581a, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Sun Feb 25 03:42:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272711, encodeId=d3f412e2711d4, content=<a href='/topic/show?id=d04f440581e' target=_blank style='color:#2F92EE;'>#大麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44058, encryptionId=d04f440581e, topicName=大麻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Thu Dec 14 23:42:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365637, encodeId=4981136563e7f, content=<a href='/topic/show?id=41fa21e036' target=_blank style='color:#2F92EE;'>#AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2170, encryptionId=41fa21e036, topicName=AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbcc223, createdName=cooco, createdTime=Thu Dec 14 23:42:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269161, encodeId=82b826916144, content=学习学习.了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Dec 13 17:06:05 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269075, encodeId=28ee2690e5a4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/DYAIOgq83er6Gnp47UKDBUh7BiadBKe2SjdBiaibNuYmwTGkrrE34N3iaoneZnFibSziaXicAMbqIkTod8ibbI9nTwOB7w/0, createdBy=9fa32173975, createdName=兰亭序123, createdTime=Wed Dec 13 09:12:40 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269074, encodeId=8fb32690e48d, content=学习一下知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Wed Dec 13 09:10:36 CST 2017, time=2017-12-13, status=1, ipAttribution=)]
    2017-12-13 1dd8c52fm63(暂无匿称)

    学习学习.了解了解

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2003358, encodeId=24092003358c6, content=<a href='/topic/show?id=5012890397' target=_blank style='color:#2F92EE;'>#HIV患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8903, encryptionId=5012890397, topicName=HIV患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Thu May 17 08:42:00 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335876, encodeId=51803358e66b, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55a22015915, createdName=1e1ff052m13(暂无匿称), createdTime=Thu Aug 02 23:36:43 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033858, encodeId=3d6b20338581a, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Sun Feb 25 03:42:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272711, encodeId=d3f412e2711d4, content=<a href='/topic/show?id=d04f440581e' target=_blank style='color:#2F92EE;'>#大麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44058, encryptionId=d04f440581e, topicName=大麻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Thu Dec 14 23:42:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365637, encodeId=4981136563e7f, content=<a href='/topic/show?id=41fa21e036' target=_blank style='color:#2F92EE;'>#AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2170, encryptionId=41fa21e036, topicName=AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbcc223, createdName=cooco, createdTime=Thu Dec 14 23:42:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269161, encodeId=82b826916144, content=学习学习.了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Dec 13 17:06:05 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269075, encodeId=28ee2690e5a4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/DYAIOgq83er6Gnp47UKDBUh7BiadBKe2SjdBiaibNuYmwTGkrrE34N3iaoneZnFibSziaXicAMbqIkTod8ibbI9nTwOB7w/0, createdBy=9fa32173975, createdName=兰亭序123, createdTime=Wed Dec 13 09:12:40 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269074, encodeId=8fb32690e48d, content=学习一下知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Wed Dec 13 09:10:36 CST 2017, time=2017-12-13, status=1, ipAttribution=)]
    2017-12-13 兰亭序123

    学习了

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2003358, encodeId=24092003358c6, content=<a href='/topic/show?id=5012890397' target=_blank style='color:#2F92EE;'>#HIV患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8903, encryptionId=5012890397, topicName=HIV患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Thu May 17 08:42:00 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335876, encodeId=51803358e66b, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55a22015915, createdName=1e1ff052m13(暂无匿称), createdTime=Thu Aug 02 23:36:43 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033858, encodeId=3d6b20338581a, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Sun Feb 25 03:42:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272711, encodeId=d3f412e2711d4, content=<a href='/topic/show?id=d04f440581e' target=_blank style='color:#2F92EE;'>#大麻#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44058, encryptionId=d04f440581e, topicName=大麻)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Thu Dec 14 23:42:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365637, encodeId=4981136563e7f, content=<a href='/topic/show?id=41fa21e036' target=_blank style='color:#2F92EE;'>#AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2170, encryptionId=41fa21e036, topicName=AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbcc223, createdName=cooco, createdTime=Thu Dec 14 23:42:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269161, encodeId=82b826916144, content=学习学习.了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Dec 13 17:06:05 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269075, encodeId=28ee2690e5a4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/DYAIOgq83er6Gnp47UKDBUh7BiadBKe2SjdBiaibNuYmwTGkrrE34N3iaoneZnFibSziaXicAMbqIkTod8ibbI9nTwOB7w/0, createdBy=9fa32173975, createdName=兰亭序123, createdTime=Wed Dec 13 09:12:40 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269074, encodeId=8fb32690e48d, content=学习一下知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Wed Dec 13 09:10:36 CST 2017, time=2017-12-13, status=1, ipAttribution=)]
    2017-12-13 flysky120

    学习一下知识了

    0

相关资讯

Lancet Infect Dis:发现治疗HIV失败的风险因素,敦促世卫组织治疗指南更新

南非一项研究显示,接受抗逆转录病毒治疗(ART)的艾滋病毒阳性患者的低水平病毒血症(LLV)是治疗失败的重要风险因素。

Sci Rep:靶向隧道纳米管介导的远距离细胞间通讯可阻断HIV的传播

细胞间通讯对于多细胞系统的发展来说是必需的,且是由可溶性因子、外泌体、间隙连接(GJ)通道和最近描述的隧道纳米管(TNTs)协调进行。既往研究以及我们以前的研究都已经证明TNT样结构大多存在于致病条件下,包括HIV感染。然而,TNTs的性质、功能以及交流属性仍然不甚了解。本研究中,我们发现,HIV感染诱导的TNTs在其膜延伸的末端具有功能性GJs,且TNTs在HIV感染期间介导远距离GJ通信。在H

Lancet Infect Dis:警告!艾滋病毒耐药性正在不断攀升,是否会导致HIV大流行?

发表在《柳叶刀》上的一份最新研究中,科学家们研究了开始接受抗逆转录病毒治疗的数据,发现人们对非核苷类逆转录酶抑制剂的抗药性越来越多,那些发现对于全球艾滋病的防治工作起到警告的作用。

Ann Oncol:法国科学家证实癌症药可以扫荡HIV的藏身之地,清空HIV病毒

近期,一个偶然的发现引起了医学界的关注,来自法国的医生发现了第一种证据,证明一种抗癌药物可以消灭人类感染艾滋病毒的细胞。

北京协和医院发现世界首例成人HIV抗体阴性艾滋病合并KS病例

近日,记者从北京协和医院获悉,该院呼吸内科、感染内科、病理科联合报道了世界首例成人HIV抗体阴性艾滋病合并肺卡波西肉瘤病例,发表在最新一期的《临床呼吸杂志》(Clinical Respiratory Jounal论文链接)上。

Sci Transl Med:震惊!双盲研究显示HIV疫苗在病毒抑制中无效,HIV攻克之路异常艰难

来自美国和加拿大的一大组研究人员对HIV疫苗的有效性进行了一项随机的双盲研究,震惊的发现它在抑制病毒方面是无效的。发表在(Science Translational Medicine)上的论文中,描述了他们的研究,他们发现了什么,以及他们为什么相信他们的工作为医学研究社区提供了一个宝贵的教训,说明了安慰剂对照研究的重要性。

Baidu
map
Baidu
map
Baidu
map